View all cases
UPC APP 15/2025
EP2401365 · REENGINEERING MRNA PRIMARY STRUCTURE FOR ENHANCED PROTEIN PRODUCTION
- Case details
- Status—ActionProcedural applicationCategoryConfidentiality (RoP 262A / 262.2)
- Parties
- Respondents
- BioNTech SEOperating co.
- BioNTech Manufacturing GmbHOperating co.
- BioNTech Manufacturing Marburg GmbHOperating co.
- BioNTech Innovative Manufacturing Services GmbHOperating co.
- BioNTech Europe GmbHOperating co.
- Pfizer Manufacturing Belgium NVOperating co.
- Pfizer SASOperating co.
- Pfizer ABOperating co.
- Pfizer Inc.Operating co.
Representatives- Christine Kanz-Hoyng Rokh Monegier
- Tobias J. Hessel-Clifford Chance Partnerschaft mbB
- Division
- Munich LD
- Judges
- Technology
- ChemistryBiotechnology
- Language
- —
- First decided
- Mar 10, 2025
How this compares
How long the court takes to reach a first decision.
| Median days to first decision | |
|---|---|
| All UPC | 124 |
| Munich LD | Locked |
| Judge András Kupecz | Locked |
At the UPC: Promosome LLC (15 cases)·BioNTech Group (21 cases)
Start 14-day free trialAlready a user? Sign in
Related cases
All proceedings on this patentThis dispute contains 14 other proceedings
UPC CoA 146/2026·UPC CoA 147/2026·UPC CoA 148/2026·UPC CFI 2819/2026·UPC CFI 2821/2026 and 9 more
Decisions
- 2025-03-10Application RoP262APublic
Summary: The Munich Local Division granted Promosome LLC's application under Rule 262A RoP for confidentiality protection of certain exhibits (VB 4a and VB 4b) in its infringement action against BioNTech and Pfizer entities.
Show the legal issues (2)
- Confidentiality Rule 262A RoP
- Trade secrets
Documents
- 21772AC18D828EF187CAB78342AE12E9_en.pdf2025-03-10EN